Anyone who thinks that the term "the dismal science" refers to economics is clearly not involved in clinical trials for Alzheimer's disease, an indication which has dashed the last 13 Phase III trials attempting to make a dent in it. Read More
It will be a while before all the provisions of the Jumpstart Our Business Startups (JOBS) Act kick in, but a number of emerging growth biotechs are already queuing for an initial public offering (IPO). Read More
